ReviewCurrent neuropharmacology2017
Melatonin as a Therapeutic Resource for Inflammatory Visual Diseases.
Review in Current neuropharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Melatonin in Clinical Practice: Grey Zones Between Chronobiology, Insomnia and Consumer Supplementation.Clocks & sleep · 2026Article
- The Therapeutic Trip of Melatonin Eye Drops: From the Ocular Surface to the Retina.Pharmaceuticals (Basel, Switzerland) · 2024Review
- The Role and Therapeutic Potential of Melatonin in Degenerative Fundus Diseases: Diabetes Retinopathy and Age-Related Macular Degeneration.Drug design, development and therapy · 2024Review
- Short-Wavelength Light-Blocking Filters and Oral Melatonin Administration in Patients With Retinitis Pigmentosa: Protocol for a Randomized Controlled Trial.JMIR research protocols · 2023Article
- Is Melatonin the "Next Vitamin D"?: A Review of Emerging Science, Clinical Uses, Safety, and Dietary Supplements.Nutrients · 2022Review
- Synthesis, Pharmacokinetic Characterization and Antioxidant Capacity of Carotenoid Succinates and Their Melatonin Conjugates.Molecules (Basel, Switzerland) · 2022Article
- Dietary supplements in retinal diseases, glaucoma, and other ocular conditions.Journal of preventive medicine and hygiene · 2022Review
- Short prolactin isoforms are expressed in photoreceptors of canine retinas undergoing retinal degeneration.Scientific reports · 2021Article
- Therapeutic Effects of Melatonin on Ocular Diseases: Knowledge Map and Perspective.Frontiers in pharmacology · 2021Article
- Intravitreous delivery of melatonin affects the retinal neuron survival and visual signal transmission:Drug delivery · 2020Article
- Mechanisms behind Retinal Ganglion Cell Loss in Diabetes and Therapeutic Approach.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUveitis and optic neuritis are prevalent ocular inflammatory diseases, and highly damaging ocular conditions. Both diseases are currently treated with corticosteroids, but they do not have adequate efficacy and are often associated with severe side effects. Thus, uveitis and optic neuritis remain a challenging field to ophthalmologists and a significant public health concern.
objectiveThis review summarizes findings showing the benefits of a treatment with melatonin in experimental models of these inflammatory ocular diseases.
resultsOxidative and nitrosative damage, tumor necrosis factor, and prostaglandin production have been involved in the pathogeny of uveitis and optic neuritis. Melatonin is an efficient antioxidant and antinitridergic, and has the ability to reduce prostaglandin and tumor necrosis factor levels both in the retina and optic nerve. Moreover, melatonin not only prevents functional and structural consequences of experimental uveitis and optic neuritis, but it is also capable of suppressing the actively ongoing ocular inflammatory response.
conclusionsSince melatonin protects ocular tissues against inflammation, it could be a potentially useful anti-inflammatory therapy in ophthalmology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.